Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28737015 | 0.74 | MERTK (0.33) | — | |
| SCHEMBL6488030 | 0.73 | CYP1A2 (0.35) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29587068 | 0.72 | AKT1 (0.34) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL398730 | 0.72 | AKT1 (0.34) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22547494 | 0.72 | CYP1A2 (0.34) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24388896 | 0.72 | CA1 (0.36) | — | |
| SCHEMBL28987116 | 0.71 | CRHBP (0.35) | — | |
| SCHEMBL17364601 | 0.71 | S1PR4 (0.33) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16659004 | 0.71 | LMNA (0.33) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20897575 | 0.70 | CYP3A4 (0.38) | CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-3601239-B1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2024-07-31 | — | — | EP | disclosed |
| WO-2022089406-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海青煜医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| WO-2020156242-A1 | SHP2 INHIBITOR AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
| EP-3601239-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172984-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | CYP1A2 3758/4885CYP3A4 4643/4885CYP2D6 3856/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | CYP1A2 3879/4885CYP3A4 4689/4885CYP2D6 3936/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | CYP1A2 3758/4885CYP3A4 4643/4885CYP2D6 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.